Cargando…

Role of teriparatide in treatment of glucocorticoid-induced osteoporosis

Glucocorticoids are commonly used in various fields within medicine. One of their most common and clinically significant side effects is glucocorticoid-induced osteoporosis (GIOP). GIOP is a disease leading to progressive decreases in bone mineral density, decreased bone strength, and increased risk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lau, Arthur N, Adachi, Jonathan D
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2963159/ https://www.ncbi.nlm.nih.gov/pubmed/21063460 http://dx.doi.org/10.2147/TCRM.S7776

Ejemplares similares

Management of glucocorticoids-induced osteoporosis: role of teriparatide
por: Migliaccio, Silvia, et al.
Publicado: (2009)

Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis
por: Dore, Robin K
Publicado: (2013)

Improvement in health-related quality of life in osteoporosis patients treated with teriparatide
por: Lau, Arthur N, et al.
Publicado: (2008)

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2020)

Teriparatide in the management of osteoporosis
por: Bodenner, Donald, et al.
Publicado: (2007)

Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment
por: Gagnon, Claudia, et al.
Publicado: (2008)

Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
por: Seno, Takahiro, et al.
Publicado: (2016)

Update on the safety and efficacy of teriparatide in the treatment of osteoporosis
por: Minisola, Salvatore, et al.
Publicado: (2019)

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden
por: Murphy, Daniel R, et al.
Publicado: (2012)

Teriparatide – Indications beyond osteoporosis
por: Cheng, Marilyn Lee, et al.
Publicado: (2012)

Therapy of Osteoporosis in Men with Teriparatide
por: Cusano, Natalie E., et al.
Publicado: (2011)

Profile of teriparatide in the management of postmenopausal osteoporosis
por: Sikon, Andrea, et al.
Publicado: (2010)

Teriparatide for osteoporosis: importance of the full course
por: Lindsay, R., et al.
Publicado: (2016)

Treatment of osteoporosis with teriparatide: The Slovenian experience
por: Kocjan, Tomaz, et al.
Publicado: (2021)

PINP as a biological response marker during teriparatide treatment for osteoporosis
por: Krege, J. H., et al.
Publicado: (2014)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

Comparative Effects of Teriparatide and Risedronate in Glucocorticoid-Induced Osteoporosis in Men: 18-Month Results of the EuroGIOPs Trial
por: Glüer, Claus-C, et al.
Publicado: (2013)

A Case of Teriparatide on Pregnancy-Induced Osteoporosis
por: Lee, Seok Hong, et al.
Publicado: (2013)

An effect comparison of alendronate and teriparatide in patients with glucocorticoid-induced osteoporosis: A protocol for systematic review and meta-analysis
por: Liang, Na, et al.
Publicado: (2022)

Understanding and Managing Corticosteroid-Induced Osteoporosis
por: Kobza, Alexandra O, et al.
Publicado: (2021)

The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials
por: Liu, Zhi-Ming, et al.
Publicado: (2022)

Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
por: Yuan, Chuanjian, et al.
Publicado: (2023)

Improvement in Glucocorticoid-Induced Osteoporosis on Switching from Bisphosphonates to Once-Weekly Teriparatide: A Randomized Open-Label Trial
por: Nanki, Toshihiro, et al.
Publicado: (2022)

Treatment responses with once-weekly teriparatide therapy for osteoporosis
por: Shiraki, M., et al.
Publicado: (2016)

Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis
por: Farahmand, P., et al.
Publicado: (2013)

Glucocorticoid-induced osteoporosis: an update
por: Compston, Juliet
Publicado: (2018)

The molecular etiology and treatment of glucocorticoid-induced osteoporosis
por: Peng, Cheng-Huan, et al.
Publicado: (2021)

Review of Current Real-World Experience with Teriparatide as Treatment of Osteoporosis in Different Patient Groups
por: Hauser, Barbara, et al.
Publicado: (2021)

Update on Glucocorticoid Induced Osteoporosis
por: Cho, Soo-Kyung, et al.
Publicado: (2021)

Glucocorticoid‐induced osteoporosis in rheumatic diseases
por: Pereira, Rosa Maria Rodrigues, et al.
Publicado: (2010)

Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis
por: Taheri, Saeed, et al.
Publicado: (2019)

THU441 Teriparatide As Treatment For Severe Osteoporosis In Lung Transplant Recipients
por: Muir, Christopher Alan, et al.
Publicado: (2023)

Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options
por: Payer, Juraj, et al.
Publicado: (2010)

Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis
por: Serefoglu, Ege Can, et al.
Publicado: (2010)

Glucocorticoid-induced osteoporosis
por: Briot, Karine, et al.
Publicado: (2015)

Glucocorticoid-induced Osteoporosis
por: Cherian, Kripa Elizabeth, et al.
Publicado: (2017)

Dilemmas in the diagnosis and management of osteoporosis in a patient with alkaptonuria: Successful treatment with teriparatide
por: Ebrahim, Ismail C., et al.
Publicado: (2022)

Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis
por: Bonafede, M. M., et al.
Publicado: (2015)

Zebrafish models for glucocorticoid-induced osteoporosis
por: Lin, Wen-Ying, et al.
Publicado: (2022)

The critical role of T cells in glucocorticoid-induced osteoporosis
por: Song, Lin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oa9nismlv03h31ti14u5srpaq2